Commentary

Day 2 at the Alzheimer's Association International Conference featured a poster presentation from Dr. Chuang-Kuo Wu on his research to better understand and diagnose posterior cortical atrophy (video) and a lecture from Dr. S. Ahmad Sajjadi on higher education as a protective factor against cognitive decline in the oldest-old. Over 5,600 researchers and clinicians are in attendance at the conference this year, providing UCI MIND exciting opportunities to learn from and share findings with our global partners in the fight to solve Alzheimer's disease and related dementias.

Today, the Centers for Disease Control (CDC) confirmed what researchers at UCI MIND have long known to be true: Alzheimer’s disease is an escalating public health crisis that requires increased attention. The report examined rates of death due to Alzheimer’s disease from 1999 to 2014 and found a staggering 55% national increase over that time. Rates were higher among women than men and among non-Hispanic whites compared to other racial/ethnic populations. However, over this time period Alzheimer's death rates saw a greater increase within minority groups compared to non-Hispanic whites. The report also confirmed that the number of Alzheimer’s deaths is highest in…

UCI MIND investigators Mathew Blurton-Jones, PhD, Assistant Professor of Neurobiology & Behavior, Wayne Poon, PhD, Director of UCI MIND Tissue Repository, and Edsel Abud, MD/PhD student, have created a method to generate brain cells called microglia using human skin cells. Here, they discuss their findings and what it means for Alzheimer's disease research in an interview with Chelsea Cox, Associate Director of Education: What is microglia and what role does it play in Alzheimer's disease? Poon: Microglia are the immune cells of the brain. They play a big role in the inflammation of the brain that occurs in Alzheimer’s disease. How can…

by Joshua Grill, PhD April 12, 2017 On April 6, the US Food and Drug Administration (FDA) partially reversed an earlier decision to halt direct-to-consumer (DTC) genetic testing by the company 23andMe, a personal genomics company based in Silicon Valley. The new decision approves the company to provide “genetic health risk reports” for 10 diseases, including 8 rare disorders—Alpha-1 Antitrypsin Deficiency, Celiac Disease, Early-Onset Primary Dystonia, Factor XI Deficiency, G6PD Deficiency, Gaucher Disease, Hereditary Hemochromatosis, and Hereditary Thrombophilia—and two common age-related neurological disorders—Parkinson’s disease and Alzheimer’s disease (AD). After age, the strongest risk factor for AD is genetics. The e4…

by Joshua Grill, PhD Letters: A quick cure for Alzheimer's? OC Register, March 29, 2017 Re: “Is Alzheimer’s treatment of injecting stem cells into the brain a breakthrough or quackery?” : The Register recently reported on a local neurosurgeon who is injecting liposuctioned stem cell serum into the brain of a patient with Alzheimer’s disease for $10,000 per treatment. The neurosurgeon says the patient is improving...